Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

The OPTION trial revealed non-inferior efficacy for all-cause death, stroke, or systemic embolism at 36 months. The WATCHMAN ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

For more information about the updated device, please call the ProCare Odessa Heart Institute at 432-337-3117 or visit the Watchman website here. For the latest news, weather, sports, and ...

Click to share on Facebook (Opens in new window) Click to email a link to a friend (Opens in new window) Click to print (Opens in new window) Click to share on X (Opens in new window) The ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Larry ...

Although some of the trial’s methodology was critiqued, the results provide fodder for shared decision-making discussions.

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.

(BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device. The device demonstrated superior ...